MCID: PTT006
MIFTS: 52

Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Pituitary Adenoma

MalaCards integrated aliases for Pituitary Adenoma:

Name: Pituitary Adenoma 12 29 55 15 73
Pituitary Neoplasms 44 73
Adenoma of the Pituitary Gland 12
Pituitary Adenomas 37
Adenoma, Pituitary 40

Classifications:



External Ids:

Disease Ontology 12 DOID:3829
MeSH 44 D010911
NCIt 50 C3329
KEGG 37 H01102

Summaries for Pituitary Adenoma

MalaCards based summary : Pituitary Adenoma, also known as pituitary neoplasms, is related to functionless pituitary adenoma and retinoblastoma. An important gene associated with Pituitary Adenoma is MIR15A (MicroRNA 15a
miR-15a and miR-16-1 are expressed at lower levels in pituitary adenomas as compared to normal pituitary tissue. Moreover, their expression inversely correlates with tumor diameter and with RARS expression (P ), and among its related pathways/superpathways are Transcriptional misregulation in cancer and ErbB signaling pathway. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and brain.

Wikipedia : 76 Pituitary adenomas are tumors that occur in the pituitary gland. Pituitary adenomas are generally... more...

Related Diseases for Pituitary Adenoma

Diseases in the Pituitary Adenoma family:

Pituitary Adenoma 1, Multiple Types Pituitary Adenoma 5, Multiple Types
Pituitary Adenoma 3, Multiple Types

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 functionless pituitary adenoma 34.4 HOTAIR MEG3
2 retinoblastoma 30.2 HOTAIR MALAT1 MEG3 MIRLET7E
3 glioma 30.1 CCAT2 H19 HOTAIR MALAT1 MEG3 MIR15A
4 thyroid cancer, nonmedullary, 1 29.5 H19 HOTAIR MALAT1 MEG3 MIR138-2 MIR15A
5 leukemia, chronic lymphocytic 29.3 MIR132 MIR15A MIR16-1 MIR223 MIR24-1
6 glioblastoma 29.2 H19 HOTAIR MALAT1 MEG3 MIR197 MIR24-1
7 melanoma 29.1 H19 HOTAIR MALAT1 MEG3 MIR149 MIR15A
8 prostate cancer 28.5 CCAT2 H19 HOTAIR MALAT1 MEG3 MIR149
9 pituitary adenoma, prolactin-secreting 12.6
10 acth-secreting pituitary adenoma 12.5
11 familial isolated pituitary adenoma 12.5
12 pituitary adenoma 1, multiple types 12.5
13 pituitary adenoma 4, acth-secreting 12.5
14 pituitary adenoma 5, multiple types 12.4
15 pituitary adenoma 3, multiple types 12.4
16 pituitary adenoma 2, growth hormone-secreting 12.4
17 growth hormone secreting pituitary adenoma 12.2
18 functioning pituitary adenoma 12.2
19 aip-related familial isolated pituitary adenomas 12.1
20 non-functioning pituitary adenoma 12.1
21 silent pituitary adenoma 12.1
22 null pituitary adenoma 12.0
23 acroleukopathy, symmetric 11.6
24 chromophobe adenoma 11.5
25 acromegaly 11.4
26 conn's syndrome 11.3
27 pituicytoma 11.3
28 adrenal gland hyperfunction 11.3
29 chiasmal syndrome 11.3
30 adenoma 11.2
31 tsh producing pituitary tumor 11.1
32 somatomammotropinoma 11.1
33 acth-independent macronodular adrenal hyperplasia 11.0
34 chromosome xq26.3 duplication syndrome 11.0
35 hyperpituitarism 11.0
36 paroxysmal hemicrania 11.0
37 gastrointestinal defects and immunodeficiency syndrome 11.0
38 triple-receptor negative breast cancer 11.0 HOTAIR MALAT1
39 esophagus squamous cell carcinoma 10.9 HOTAIR MEG3
40 vulva squamous cell carcinoma 10.8 MALAT1 MEG3
41 prostate disease 10.8 H19 MALAT1 MEG3
42 gastric cardia adenocarcinoma 10.8 H19 HOTAIR MEG3
43 malignant glioma 10.7 H19 MALAT1 MEG3
44 gastrointestinal system cancer 10.7 H19 HOTAIR MALAT1
45 bladder urothelial carcinoma 10.6 HOTAIR MALAT1 MEG3
46 kidney cancer 10.6 H19 HOTAIR MALAT1 MEG3
47 clear cell renal cell carcinoma 10.5 CCAT2 MALAT1 MEG3
48 gallbladder cancer 10.5 H19 HOTAIR MALAT1 MEG3
49 dermatomyositis 10.5 MIR132 MIR223
50 nonalcoholic fatty liver disease 10.5 MIR132 MIR16-1 MIRLET7E

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Menthol Approved Phase 4 2216-51-5 16666
4
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 83150-76-9 383414 6400441
5
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 38916-34-6, 51110-01-1 53481605
8 lanreotide Approved Phase 4 108736-35-2
9
Cefazolin Approved Phase 4 25953-19-9 656510 33255
10
Cefdinir Approved Phase 4 91832-40-5 6915944
11
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
15
Liraglutide Approved Phase 4 204656-20-2 44147092
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Zinc Approved, Investigational Phase 4 7440-66-6 23994
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
20
Butyric Acid Experimental, Investigational Phase 4,Not Applicable 107-92-6 264
21
Lactitol Investigational Phase 4 585-86-4 3871
22 Anesthetics Phase 4,Phase 1,Not Applicable
23 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
25 Cortisol succinate Phase 4,Phase 3,Phase 2,Not Applicable
26 glucocorticoids Phase 4,Phase 2,Not Applicable
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
28 Hormones Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
30 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2,Not Applicable
31 Hydrocortisone acetate Phase 4,Phase 3,Phase 2,Not Applicable
32 Hydrocortisone-17-butyrate Phase 4,Not Applicable
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 insulin Phase 4,Phase 2
35 Insulin, Globin Zinc Phase 4,Phase 2
36 Antiparkinson Agents Phase 4,Phase 3,Phase 2
37 Dopamine Agents Phase 4,Phase 3,Phase 2
38 Dopamine agonists Phase 4,Phase 3,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 4,Not Applicable
41 Antibiotics, Antitubercular Phase 4,Not Applicable
42 HIV Protease Inhibitors Phase 4,Not Applicable
43
protease inhibitors Phase 4,Not Applicable
44 Angiopeptin Phase 4
45 Anti-Infective Agents Phase 4,Phase 2
46 Antimalarials Phase 4
47 Antiparasitic Agents Phase 4
48 Antiprotozoal Agents Phase 4
49 Antitubercular Agents Phase 4
50 cefuroxime axetil Phase 4

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
3 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
4 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
5 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
6 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
7 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
8 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
9 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
10 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
11 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
12 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
13 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
14 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
15 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
16 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
17 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
18 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
19 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
20 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
21 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
22 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
23 Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency Terminated NCT00630487 Phase 3 Placebo;Somatropin
24 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
25 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
26 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
27 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
28 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
29 An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly Completed NCT00171730 Phase 2 Pasireotide
30 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
31 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
32 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
33 Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy Recruiting NCT01849484 Phase 2
34 Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas Recruiting NCT01444209 Phase 2
35 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
36 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2 R-roscovitine
37 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
38 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
39 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
40 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
41 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
42 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
43 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
44 Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Withdrawn NCT01203618 Phase 2 Farletuzumab
45 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Recruiting NCT02769533 Phase 1 OTL0038;Benadryl
46 Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT Recruiting NCT03404414 Phase 1 18F-FDG
47 Intraoperative Imaging of Pituitary Adenomas by OTL Active, not recruiting NCT02629549 Phase 1 OTL38
48 The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor Unknown status NCT01377701
49 Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma Unknown status NCT00598949
50 Genome-wide Association Study of Pituitary Tumors Unknown status NCT01442220

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

# Genetic test Affiliating Genes
1 Pituitary Adenoma 29

Anatomical Context for Pituitary Adenoma

MalaCards organs/tissues related to Pituitary Adenoma:

41
Pituitary, Thyroid, Brain, Endothelial, Liver, Testes, Bone

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 1717)
# Title Authors Year
1
Top 100 Most-Cited Articles on Pituitary Adenoma: A Bibliometric Analysis. ( 29870843 )
2018
2
Association of retinal nerve fibre layer thickness with quantitative magnetic resonance imaging data of the optic chiasm in pituitary adenoma patients. ( 29398198 )
2018
3
Clinical and pathological characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. ( 29981466 )
2018
4
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
5
Massive pleural and pericardial effusion due to hypothyroidism in a patient with a surgically treated thyroid-stimulating hormone-producing pituitary adenoma. ( 29757110 )
2018
6
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. ( 29288766 )
2018
7
Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an <i>AIP</i> Mutation-Positive Family. ( 29849625 )
2018
8
Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. ( 29909598 )
2018
9
Spontaneous improvement of cutis verticis gyrata secondary to acromegaly following surgical treatment of pituitary adenoma. ( 29927514 )
2018
10
Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5. ( 29309750 )
2018
11
MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma. ( 29399147 )
2018
12
Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly. ( 29782043 )
2018
13
Clinical outcomes of endoscopic versus microscopic trans-sphenoidal surgery for large pituitary adenoma. ( 29417847 )
2018
14
EVALUATION OF CARDIOVASCULAR RISK WITH ARTERIAL STIFFNESS IN PATIENTS WITH NON-FUNCTIONING PITUITARY ADENOMA. ( 29975581 )
2018
15
Primary meningeal melanocytoma in sellar region, simulating a nonfunctioning pituitary adenoma; a case report and literature review. ( 29382618 )
2018
16
The Predictive Value of Suprasellar Extension for Visual Function Evaluation in Chinese Patients with Nonfunctioning Pituitary Adenoma with Optic Chiasm Compression. ( 29857216 )
2018
17
Data of phosphoproteomic analysis of non-functioning pituitary adenoma. ( 29900237 )
2018
18
Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm. ( 29404245 )
2018
19
Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs. ( 29864631 )
2018
20
Perioperative serum cortisol levels in ACTH sufficient and ACTH deficient patients during transsphenoidal surgery of pituitary adenoma. ( 29968225 )
2018
21
A thyrotropin-secreting pituitary adenoma treated with radiosurgery: Long-term outcomes. ( 29426625 )
2018
22
Diabetes Insipidus following Endoscopic Transsphenoidal Surgery for Pituitary Adenoma. ( 29868315 )
2018
23
Universal Sellar Anatomical Reconstruction Using the Sellar Floor Flap after Endoscopic Pituitary Adenoma Surgery. ( 29436283 )
2018
24
Mortality in patients with non-functioning pituitary adenoma. ( 29344906 )
2018
25
Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma. ( 29955610 )
2018
26
TSH-STAINING PITUITARY ADENOMA: A RARE ENTITY WITH CHANGING FACETS. ( 29949433 )
2018
27
Evaluation of Complications and Costs During Overlapping Transsphenoidal Surgery in the Treatment of Pituitary Adenoma. ( 29897572 )
2018
28
The clinical value of the multi-channel PVEP and PERG in the diagnosis and management of the patient with pituitary adenoma: a case report. ( 29968203 )
2018
29
Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma. ( 29910227 )
2018
30
Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery. ( 29450811 )
2018
31
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). ( 29299820 )
2018
32
Case report of recurrent atrial fibrillation induced by thyrotropin-secreting pituitary adenoma with Graves' disease. ( 29901603 )
2018
33
Risk category system to identify pituitary adenoma patients with<i>AIP</i>mutations. ( 29440248 )
2018
34
Endoscopic Endonasal Resection of a Suprasellar Pituitary Adenoma Mimicking Tuberculum Sellae Meningioma in a Patient with an Intrasellar Persistent Trigeminal Artery. ( 29588905 )
2018
35
Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis Based on Patients Treated Using Contemporary Techniques. ( 29678524 )
2018
36
Combined effects of resveratrol and radiation in GH3 and TtT/GF pituitary adenoma cells. ( 29872948 )
2018
37
CantA_ syndrome with coexisting familial pituitary adenoma. ( 29327300 )
2018
38
Neurosurgical image: giant pituitary adenoma and multiple aneurysms. ( 29373931 )
2018
39
Nonfunctioning Pituitary Adenoma That Changed to a Functional Gonadotropinoma. ( 29854488 )
2018
40
Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. ( 28061802 )
2017
41
Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas. ( 28214592 )
2017
42
Perioperative management of haemophilia A using recombinant factor VIII Fc fusion protein in a patient undergoing endoscopic nasal pituitary adenomectomy for a growth hormone-producing pituitary adenoma. ( 28906056 )
2017
43
Hypopituitarism after gamma knife radiosurgery for pituitary adenoma. ( 28537768 )
2017
44
Thyrotropic pituitary adenoma with plurihormonal immunoreactivity. ( 28879926 )
2017
45
A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. ( 28586933 )
2017
46
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. ( 27455094 )
2017
47
Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. ( 28841122 )
2017
48
Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report. ( 28865461 )
2017
49
Decreased TAp63 and I9Np63 mRNA Levels in Most Human Pituitary Adenomas Are Correlated with Notch3/Jagged1 Relative Expression. ( 28078618 )
2017
50
The &amp;quot;game&amp;quot; of glial fibrillary acidic and S100 proteins in pituitary adenomas: two players or several? ( 28660986 )
2017

Variations for Pituitary Adenoma

Copy number variations for Pituitary Adenoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

Pathways related to Pituitary Adenoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 ErbB signaling pathway hsa04012
3 Cell cycle hsa04110
4 Apoptosis hsa04210
5 Insulin signaling pathway hsa04910

Pathways related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.58 MIR15A MIR16-1 MIR223 MIR26B MIRLET7E MIRLET7F1
2 11.18 MIR132 MIR136 MIR212 MIR26B
3 10.7 MIRLET7E MIRLET7F1
4 10.23 HOTAIR MEG3

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 MIR132 MIR136 MIR15A MIR16-1 MIR197 MIR212

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.56 MIR15A MIR16-1 MIR212 MIR24-1
2 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.54 MIR138-2 MIR15A MIR16-1
3 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.49 MIR132 MIRLET7F1
4 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.48 MIR15A MIR16-1
5 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.46 MIR15A MIR223
6 positive regulation of endothelial cell apoptotic process GO:2000353 9.43 MIR15A MIR24-1
7 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.4 MIR15A MIR223
8 miRNA mediated inhibition of translation GO:0035278 9.35 MIR132 MIR138-2 MIR15A MIR16-1 MIR212
9 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.33 MIR15A MIR16-1 MIR24-1
10 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.32 MIR15A MIR16-1
11 gene silencing by miRNA GO:0035195 9.28 MIR132 MIR138-2 MIR15A MIR16-1 MIR212 MIR223

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR132 MIR138-2 MIR15A MIR16-1 MIR212 MIR223

Sources for Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....